TAM April 2024 CME Posttest

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, which contains 3 articles, the learner will be better able to:

• Summarize current information on mRNA vaccine technology and describe how it was successfully used during the COVID-19 pandemic andhas created opportunities in the ongoing search for an effective HIV-1vaccine.
• Utilize the latest recommendations for routine and special vaccinationsin people with HIV.
• Describe the experiences, clinical manifestations, and perspectives of 2physician-patients suffering from long COVID.
• Outline the long-term treatment regimen for a patient who developedhighly drug-resistant HIV with a well-documented evolution of resistance with serial genotyping and phenotyping drug resistance tests.

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.

Intended Audience

This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from April 18, 2024, to April 18, 2025. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of the contributors and do not necessarily represent the opinions or recommendations of the IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400

By clicking the link below, I acknowledge that I have read these instructions and understand them.